Purchase disclosed
Carl L. Gordon
Director
Common Stock
- Reported value
- $5M
- Reported price
- $15.00 / share
Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
Electra Therapeutics, Inc.
Last 30 daysInsiders bought $40M · 2 buyers, led by Carl L. Gordon (Director) with $20M. No qualifying insider sales.
Director
Common Stock
Director
Common Stock
Director
Common Stock
Director
Common Stock
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| Director | Common StockPurchase2 trades | 1,333,333avg $15.00 / share | $20M | Sep 21Filed Sep 23 · 2d later | 2 filings
|
| +2Director | Common StockPurchase2 trades | 1,333,333avg $15.00 / share | $20M | Sep 21Filed Sep 23 · 2d later | 2 filings
|
$35,999,991 of common-equity purchase value after transaction-age decay across 180 days.
2 distinct reporting-owner group(s). Joint rows count once; identity is not proof of discretion.
2 buying groups inside 30 transaction-date days, public by the snapshot cutoff.
At least one row increased reported same-security holdings by 10% or established a new reported position; indirect interests may overlap.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.
This reflects the filings imported so far, not a complete trading history.